Effectiveness of supplementation of Nefrosave® in Chronic Kidney Disease
Not Applicable
- Conditions
- Health Condition 1: N181- Chronic kidney disease, stage 1Health Condition 2: N182- Chronic kidney disease, stage 2 (mild)Health Condition 3: N183- Chronic kidney disease, stage 3 (moderate)
- Registration Number
- CTRI/2023/12/060567
- Lead Sponsor
- Fourrts India Laboratories Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Adult patients with diabetes mellitus or hypertension maybe diagnosed with chronic kidney disease (CKD) Stage 1, Stage 2 and up to Stage 3.
2. Adult patients with microalbuminuria result ranging from 30-300mg/day.
Exclusion Criteria
Patients with incomplete medical records with respect to the required study parameters
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in urinary albumin to creatinine ratio (uACR) from baseline to study endTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method 1. Change in microalbuminuria within treatment time period of 3 months <br/ ><br> <br/ ><br>2.Tolerability evaluated based on adverse events recorded by the treating physician during the treatment period of 3 months <br/ ><br>3.Casualty assessment of adverse events recorded by the treating physician, if anyTimepoint: 3 months